313 related articles for article (PubMed ID: 10678966)
1. Listeria monocytogenes as a short-lived delivery system for the induction of type 1 cell-mediated immunity against the p36/LACK antigen of Leishmania major.
Soussi N; Milon G; Colle JH; Mougneau E; Glaichenhaus N; Goossens PL
Infect Immun; 2000 Mar; 68(3):1498-506. PubMed ID: 10678966
[TBL] [Abstract][Full Text] [Related]
2. Enteral immunization with attenuated recombinant Listeria monocytogenes as a live vaccine vector: organ-dependent dynamics of CD4 T lymphocytes reactive to a Leishmania major tracer epitope.
Saklani-Jusforgues H; Fontan E; Soussi N; Milon G; Goossens PL
Infect Immun; 2003 Mar; 71(3):1083-90. PubMed ID: 12595418
[TBL] [Abstract][Full Text] [Related]
3. Effect of intragastric and intraperitoneal immunisation with attenuated and wild-type LACK-expressing Listeria monocytogenes on control of murine Leishmania major infection.
Soussi N; Saklani-Jusforgues H; Colle JH; Milon G; Glaichenhaus N; Goossens PL
Vaccine; 2002 Jun; 20(21-22):2702-12. PubMed ID: 12034096
[TBL] [Abstract][Full Text] [Related]
4. The combination of DNA vectors expressing IL-12 + IL-18 elicits high protective immune response against cutaneous leishmaniasis after priming with DNA-p36/LACK and the cytokines, followed by a booster with a vaccinia virus recombinant expressing p36/LACK.
Tapia E; Pérez-Jiménez E; López-Fuertes L; Gonzalo R; Gherardi MM; Esteban M
Microbes Infect; 2003 Feb; 5(2):73-84. PubMed ID: 12650765
[TBL] [Abstract][Full Text] [Related]
5. Oral immunization using live Lactococcus lactis co-expressing LACK and IL-12 protects BALB/c mice against Leishmania major infection.
Hugentobler F; Di Roberto RB; Gillard J; Cousineau B
Vaccine; 2012 Aug; 30(39):5726-32. PubMed ID: 22814408
[TBL] [Abstract][Full Text] [Related]
6. Vaccination with DNA encoding the immunodominant LACK parasite antigen confers protective immunity to mice infected with Leishmania major.
Gurunathan S; Sacks DL; Brown DR; Reiner SL; Charest H; Glaichenhaus N; Seder RA
J Exp Med; 1997 Oct; 186(7):1137-47. PubMed ID: 9314562
[TBL] [Abstract][Full Text] [Related]
7. Immune responses induced by the Leishmania (Leishmania) donovani A2 antigen, but not by the LACK antigen, are protective against experimental Leishmania (Leishmania) amazonensis infection.
Coelho EA; Tavares CA; Carvalho FA; Chaves KF; Teixeira KN; Rodrigues RC; Charest H; Matlashewski G; Gazzinelli RT; Fernandes AP
Infect Immun; 2003 Jul; 71(7):3988-94. PubMed ID: 12819086
[TBL] [Abstract][Full Text] [Related]
8. Protective immune response against cutaneous leishmaniasis by prime/booster immunization regimens with vaccinia virus recombinants expressing Leishmania infantum p36/LACK and IL-12 in combination with purified p36.
Gonzalo RM; Rodríguez JR; Rodríguez D; González-Aseguinolaza G; Larraga V; Esteban M
Microbes Infect; 2001 Jul; 3(9):701-11. PubMed ID: 11489418
[TBL] [Abstract][Full Text] [Related]
9. Transcutaneous immunization using SLA or rLACK skews the immune response towards a Th1 profile but fails to protect BALB/c mice against a Leishmania major challenge.
Lakhal-Naouar I; Koles N; Rao M; Morrison EB; Childs JM; Alving CR; Aronson NE
Vaccine; 2019 Jan; 37(3):516-523. PubMed ID: 30528328
[TBL] [Abstract][Full Text] [Related]
10. Vaccination with TAT-antigen fusion protein induces protective, CD8(+) T cell-mediated immunity against Leishmania major.
Kronenberg K; Brosch S; Butsch F; Tada Y; Shibagaki N; Udey MC; von Stebut E
J Invest Dermatol; 2010 Nov; 130(11):2602-10. PubMed ID: 20574442
[TBL] [Abstract][Full Text] [Related]
11. Protective vaccination with promastigote surface antigen 2 from Leishmania major is mediated by a TH1 type of immune response.
Handman E; Symons FM; Baldwin TM; Curtis JM; Scheerlinck JP
Infect Immun; 1995 Nov; 63(11):4261-7. PubMed ID: 7591056
[TBL] [Abstract][Full Text] [Related]
12. Leishmania donovani p36(LACK) DNA vaccine is highly immunogenic but not protective against experimental visceral leishmaniasis.
Melby PC; Yang J; Zhao W; Perez LE; Cheng J
Infect Immun; 2001 Aug; 69(8):4719-25. PubMed ID: 11447143
[TBL] [Abstract][Full Text] [Related]
13. MVA-LACK as a safe and efficient vector for vaccination against leishmaniasis.
Pérez-Jiménez E; Kochan G; Gherardi MM; Esteban M
Microbes Infect; 2006 Mar; 8(3):810-22. PubMed ID: 16504562
[TBL] [Abstract][Full Text] [Related]
14. A single intramuscular injection with an adenovirus-expressing IL-12 protects BALB/c mice against Leishmania major infection, while treatment with an IL-4-expressing vector increases disease susceptibility in B10.D2 mice.
Gabaglia CR; Pedersen B; Hitt M; Burdin N; Sercarz EE; Graham FL; Gauldie J; Braciak TA
J Immunol; 1999 Jan; 162(2):753-60. PubMed ID: 9916695
[TBL] [Abstract][Full Text] [Related]
15. Targeting Leishmania major Antigens to Dendritic Cells In Vivo Induces Protective Immunity.
Matos I; Mizenina O; Lubkin A; Steinman RM; Idoyaga J
PLoS One; 2013; 8(6):e67453. PubMed ID: 23840706
[TBL] [Abstract][Full Text] [Related]
16. Anti-leishmania effector functions of CD4+ Th1 cells and early events instructing Th2 cell development and susceptibility to Leishmania major in BALB/c mice.
Louis JA; Conceiçao-Silva F; Himmelrich H; Tacchini-Cottier F; Launois P
Adv Exp Med Biol; 1998; 452():53-60. PubMed ID: 9889959
[TBL] [Abstract][Full Text] [Related]
17. Bacterial lipoprotein-based vaccines induce tumor necrosis factor-dependent type 1 protective immunity against Leishmania major.
Cote-Sierra J; Bredan A; Toldos CM; Stijlemans B; Brys L; Cornelis P; Segovia M; de Baetselier P; Revets H
Infect Immun; 2002 Jan; 70(1):240-8. PubMed ID: 11748189
[TBL] [Abstract][Full Text] [Related]
18. Requirements for the maintenance of Th1 immunity in vivo following DNA vaccination: a potential immunoregulatory role for CD8+ T cells.
Gurunathan S; Stobie L; Prussin C; Sacks DL; Glaichenhaus N; Iwasaki A; Fowell DJ; Locksley RM; Chang JT; Wu CY; Seder RA
J Immunol; 2000 Jul; 165(2):915-24. PubMed ID: 10878366
[TBL] [Abstract][Full Text] [Related]
19. Immunization against Leishmania major infection using LACK- and IL-12-expressing Lactococcus lactis induces delay in footpad swelling.
Hugentobler F; Yam KK; Gillard J; Mahbuba R; Olivier M; Cousineau B
PLoS One; 2012; 7(2):e30945. PubMed ID: 22348031
[TBL] [Abstract][Full Text] [Related]
20. A single intradermal administration of soluble leishmanial antigen and plasmid expressing interleukin-12 protects BALB/c mice from Leishmania major infection.
Yamakami K; Akao S; Sato M; Nitta Y; Miyazaki J; Tadakuma T
Parasitol Int; 2001 Jul; 50(2):81-91. PubMed ID: 11438430
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
